<![CDATA[FDA Approves Sonrotoclax in Relapsed/Refractory Mantle Cell Lymphoma]]>
The News The FDA has granted accelerated approval to sonrotoclax (Beqalzi) as a treatment for patients with relapsed/refractory mantle cell lymphoma (MCL) who experienced progression following treatment with at least 2 lines of prior systemic therapy, …